Shuchleib R

Language: Spanish
References: 26
Page: 38-41
PDF size: 64.37 Kb.

ABSTRACT

No abstract

REFERENCES

1. Desai MM, Zhang P, Hennessy CH. Surveillance for morbidity and mortality among older adults. United States, 1995-1996. MMWR CDC Surveill Summ 1999; 48:7-25

2. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and Selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 788- 799.

3. Bori-Segura G. Principales enfermedades reumáticas en México. Aspectos epidemiológicos e impacto socioeconómico. Rev Mex Reumat 2000; 15(6): 183-201.

4. Black HR. Isolated systolic hipertension in the elderly: lessons from clinical trials and future directions. J Hipertens 1999; 17 (Suppl 5): S49-S54.

5. Izzo JL Jr, Levy D, Black HR. Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35: 1021-1024.

6. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90: 42S-47S.

7. Pope JE, Anderson JJ, Felson DT. A meta-analyses of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 447-484.

8. Morgan T, Anderson A. Interaction of indomethacin with felodipine and enalapril. J Hypertens 1993; 11: S338.

9. Vane JR. Inhibition of prostaglandin Synthesis as a mechanism of action for aspirin-Like drugs. Nature 1971; 231(25): 232-235.

10. O’Neill GP, Ford-Hutchinson AW. Expression of mesenger mRNA for Cyclooxygenase-1 and cyclooxygenase-2 in human tissues FEBS Lett. 1993; 330: 156-160.

11. Kargman S, Charleson S, Cartwrigth M et al. Characterization of prostaglandin G/H Synthase 1 and 2 in rat, monkey and human gastrointestinal tracts. Gastroenterology 1996: 91; 111: 445-454.

12. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997; 24 Suppl. 49: 6-8.

13. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.

14. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2 selective inhibition. Am J Med 1999; 107: 65S-10S.

15. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial, Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.

16. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib an naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520- 1528.

17. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2 Specific inhibitors and cardiorenal function: A Randomized, controlled trial of Celecoxib and Rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.

18. Oates JA, Fitzgerald GA, Branch RA et al. Clinical implications of prostaglandin and Thromboxane A2 formation. N Engl J Med 1988: 319: 761.

19. Patrono C, Dunn MJ. The Clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1.

20. Johnson AG, Nguyen TV, Owe-Young R. Potential mechanism by which nonsteroidal anti-inflammatory drugs elevate bood pressure: The role of endothelin-1. J Hum Hypertens 1996; 10: 257.

21. Antiplatelet trialists collaboration. BMJ 1994; 308: 235-348.

22. Swan SK, Rudy DW, Lasseter KC et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.

23. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 14665-1470.

24. Vioxx® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., March 2000

25. Celebrex® [package insert]. Skokie, IL: Searle & Co., Inc., December 1999.

26. Whelton A, Maurath CJ, Verburg KM et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159-176.